The impact of a pathologist’s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The impact of a pathologist’s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer
Authors
Keywords
-
Journal
LUNG CANCER
Volume 166, Issue -, Pages 143-149
Publisher
Elsevier BV
Online
2022-03-05
DOI
10.1016/j.lungcan.2022.03.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Physicians’ Personalities and Behavioral Traits on Treatment-Related Decision-making for Elderly Acute Myeloid Leukemia
- (2021) Xia Wu et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability
- (2020) Alberto M. Marchevsky et al. Annals of Diagnostic Pathology
- Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray
- (2019) Hedvig Elfving et al. Clinical Lung Cancer
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
- (2019) Erik Thunnissen et al. MODERN PATHOLOGY
- Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer
- (2019) Rogier Butter et al. JOURNAL OF CLINICAL PATHOLOGY
- PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Oncology
- PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs
- (2018) Enrico Munari et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The colorectal surgeon's personality may influence the rectal anastomotic decision
- (2018) S. J. Moug et al. Colorectal Disease
- Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey
- (2018) Pierre Bories et al. HAEMATOLOGICA
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgeon leadership style and risk-adjusted patient outcomes
- (2018) Sarah P. Shubeck et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey
- (2018) Pierre Bories et al. HAEMATOLOGICA
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer
- (2017) Andreas H Scheel et al. HISTOPATHOLOGY
- PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
- (2017) Robert Brody et al. LUNG CANCER
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- (2016) Andreas H Scheel et al. MODERN PATHOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
- (2016) Charlotte Roach et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started